Sight Sciences(US:SGHT) Globenewswire·2026-01-13 12:05Core Insights - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2025, indicating a mixed performance with Q4 revenue growth but an overall decline for the year [1][5]. Financial Performance - Q4 2025 total revenue is expected to be between $20.3 million and $20.4 million, reflecting a 7% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2025 total revenue is projected to be between $77.3 million and $77.4 million, representing a 3% decrease at the estimated midpoint compared to the previous year [3]. - Cash and cash equivalents as of December 31, 2025, were approximately $92 million, slightly down from $92.4 million as of September 30, 2025 [4]. Business Developments - The company achieved significant milestones in Dry Eye reimbursement and continued momentum in Surgical Glaucoma, with Dry Eye revenues expected to increase by approximately 130% compared to the prior year [5][7]. - Surgical Glaucoma revenues are anticipated to remain flat at the estimated midpoint compared to the previous year, with expected revenues between $75.6 million and $75.7 million [7]. - The company reported cash used in Q4 totaled approximately $0.4 million, with a total of approximately $28 million used during the year, indicating operational discipline [7]. Future Outlook - The company expressed confidence in its growth outlook and operational discipline, aiming for cash flow breakeven without requiring additional equity capital [5]. - Complete financial results for Q4 and full year 2025 are expected to be announced in March 2026 [5].